Display options
Cite
Huang PS. Double down for a double win. Clin Cancer Res. 2012;18(8):2124-6doi: 10.1158/1078-0432.CCR-12-0461.
Huang, P. S. (2012). Double down for a double win. Clinical cancer research : an official journal of the American Association for Cancer Research, 18(8), 2124-6. https://doi.org/10.1158/1078-0432.CCR-12-0461
Huang, Pearl S. "Double down for a double win." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 18,8 (2012): 2124-6. doi: https://doi.org/10.1158/1078-0432.CCR-12-0461
Huang PS. Double down for a double win. Clin Cancer Res. 2012 Apr 15;18(8):2124-6. doi: 10.1158/1078-0432.CCR-12-0461. Epub 2012 Mar 05. PMID: 22392916.
Copy Download .nbib Format: NLM
Share it on

Clin Cancer Res. 2012 Apr 15;18(8):2124-6. doi: 10.1158/1078-0432.CCR-12-0461. Epub 2012 Mar 05.

Double down for a double win.

Clinical cancer research : an official journal of the American Association for Cancer Research

Pearl S Huang

Affiliations

  1. Alternative Discovery and Development, GlaxoSmithKlein, King of Prussia, Pennsylvania 19406, USA. [email protected]

PMID: 22392916 DOI: 10.1158/1078-0432.CCR-12-0461

Abstract

The rationale for using multiple inhibitors between and within the phosphoinositide 3-kinase/AKT/mTOR and RAS/MEK/ERK pathways is scientifically compelling, and a limited number of experimental agents are currently being tested in phase I combinations. Patient subpopulations, whose tumors are defined by genetic lesions, are showing promising responses to this approach.

©2012 AACR.

MeSH terms

Publication Types